Lurbinectedin is a new antitumor drug that has been approved by the US Food and Drug Administration (FDA) for the treatment of metastatic small cell lung cancer (SCLC) in patients who have previously received platinum-based chemotherapy. Lurbinectedin is a selective inhibitor of transcription, which means that it targets the process of gene expression by inhibiting RNA polymerase II, a protein that is essential for the transcription of DNA into RNA. This mechanism of action makes lurbinectedin a promising candidate for the treatment of various types of cancer, including ovarian, breast, and prostate cancer [2]. In a preclinical study, lurbinectedin demonstrated potent antitumor activity against various types of cancer, including ovarian, breast, and prostate cancer, as well as other solid tumors such as melanoma and sarcoma [3]. However, further clinical studies are needed to confirm the efficacy of lurbinectedin in these types of cancer.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458590/
[3] https://aacrjournals.org/clincancerres/article/28/13/2762/704976/Antitumor-Activity-of-Lurbinectedin-a-Selective